Sugi Predict

Sugi Predict / Compounds / SCHEMBL3426314

SCHEMBL3426314

SCHEMBL3426314

O=c1[nH]c(=O)c2cc(F)c(F)cc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ CA12 O43570 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ PARP1 P09874 1/20 0.47
▸ XDH P47989 2/20 0.44
▸ MPO P05164 2/20 0.44
▸ PDE7A Q13946 1/20 0.44
▸ PDE7B Q9NP56 1/20 0.44
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ THPO P40225 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HBB P68871 1/20 0.40
▸ PMP22 Q01453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13814616 0.88 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL29909816 0.84 ALDH1A1 (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL30504341 0.84 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL8137325 0.84 ALDH1A1 (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL13804376 0.84 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL25201307 0.84 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL2731858 0.84 ALDH1A1 (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL29909400 0.84 ALDH1A1 (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL3786399 0.81 PDE3B (0.50) KDM4EALDH1A1SMN1; SMN2XDHMPO
SCHEMBL13804379 0.80 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2HPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608317-A4 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2006-12-27 — — EP claimed
EP-1608317-A2 DIPEPTIDYL PEPTIDASE INHIBITORS Takeda San Diego, Inc. (US) 2005-12-28 — — EP claimed
US-20050004117-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2005-01-06 — — US claimed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO claimed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO claimed
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 — — CN disclosed
EP-0775697-B1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL CO (JP) 2003-02-12 — — EP disclosed
US-6413724-B1 SCREENING FOR DRUGS THAT MODULATE ENZYMES OR BIOLOGICAL RECEPTORS VERSICOR, INC. 2002-07-02 — — US disclosed
US-5994542-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-11-30 — — US disclosed
EP-0878468-A1 Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-18 — — EP disclosed
WO-1998018781-A9 FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS — 1998-08-20 — — WO disclosed
US-5756738-A Process for producing 1-substituted tetrahydroquinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-05-26 — — US disclosed
WO-1998018781-A2 FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS VERSICOR, INC. (US) 1998-05-07 — — WO disclosed
EP-0775697-A1 Process for producing 1-substituted tetrahydroquinazolindionen SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004117-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 KDM4E 2328/4885ALDH1A1 816/4885SMN1; SMN2 3765/4885
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885SMN1; SMN2 4737/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885SMN1; SMN2 4737/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885SMN1; SMN2 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.